Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRBP |
---|---|---|
09:32 ET | 1239 | 59.81 |
09:36 ET | 300 | 59.545 |
09:38 ET | 700 | 60 |
09:39 ET | 1713 | 60.16 |
09:41 ET | 1140 | 60.34 |
09:43 ET | 231 | 60.6 |
09:45 ET | 300 | 60.515 |
09:48 ET | 1008 | 60.56 |
09:50 ET | 1048 | 60.2175 |
09:52 ET | 1540 | 60 |
09:54 ET | 200 | 59.98 |
09:57 ET | 100 | 59.875 |
09:59 ET | 200 | 60 |
10:06 ET | 1215 | 59.685 |
10:08 ET | 1462 | 59.5 |
10:10 ET | 800 | 59.95 |
10:12 ET | 2200 | 60.3 |
10:15 ET | 625 | 59.9 |
10:19 ET | 468 | 59.715 |
10:21 ET | 1990 | 59.33 |
10:24 ET | 100 | 59.575 |
10:35 ET | 500 | 59.5 |
10:37 ET | 804 | 59.31 |
10:39 ET | 100 | 59.34 |
10:48 ET | 400 | 59.49 |
10:50 ET | 100 | 59.645 |
11:00 ET | 500 | 59.89 |
11:02 ET | 218 | 59.835 |
11:06 ET | 200 | 59.56 |
11:11 ET | 200 | 59.45 |
11:13 ET | 200 | 59.2 |
11:15 ET | 100 | 59 |
11:18 ET | 2200 | 59 |
11:20 ET | 100 | 59.01 |
11:22 ET | 739 | 59.02 |
11:26 ET | 2000 | 59.19 |
11:27 ET | 1366 | 58.23 |
11:29 ET | 100 | 58.525 |
11:31 ET | 230 | 58.26 |
11:36 ET | 2290 | 58.32 |
11:40 ET | 300 | 58.65 |
11:44 ET | 1056 | 58.19 |
11:45 ET | 956 | 58.1 |
11:56 ET | 2800 | 58.58 |
11:58 ET | 100 | 58.59 |
12:00 ET | 2200 | 58.82 |
12:02 ET | 171 | 58.72 |
12:07 ET | 300 | 58.425 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Corbus Pharmaceuticals Holdings Inc | 637.1M | -8.4x | --- |
GH Research PLC | 633.7M | -18.1x | --- |
LENZ Therapeutics Inc | 640.9M | -1.5x | --- |
Annexon Inc | 642.6M | -4.3x | --- |
Celcuity Inc | 630.4M | -6.3x | --- |
ProKidney Corp | 628.5M | -3.8x | --- |
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $637.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.59 |
EPS | $-6.97 |
Book Value | $-1.56 |
P/E Ratio | -8.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.